Can a drug combo fix platelet transfusion failure in blood cancer?
NCT ID NCT07635511
First seen Jun 13, 2026 · Last updated Jun 19, 2026 · Updated 1 time
Summary
This study tests whether acalabrutinib (a BTK inhibitor) alone or with bortezomib can lower harmful HLA antibodies that cause platelet transfusions to fail in blood cancer patients. About 42 adults with platelet transfusion refractoriness and high antibody levels will receive the drugs and be monitored for antibody reduction and transfusion success. The goal is to reduce bleeding risk and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HLA ANTIBODIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib maleate and bortezomib
What this could lead to
If successful, this could offer a way to reduce or eliminate harmful antibodies that make platelet transfusions ineffective in blood cancer patients, potentially lowering bleeding risk and improving survival.
What could go wrong
This is an early phase 3 trial with only 42 participants, so results may not apply broadly. The drugs can cause side effects like low blood counts, infections, or nerve damage, and the antibody reduction may not translate into better clinical outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.